ClinicalTrials.gg
RecruitingNCT07323498VREX2Updated Jan 9, 2026

Enhancing Generalization of Virtual Reality Exposure for Public Speaking Anxiety

An interventional study of VR Exposure and Standard Mental Rehearsal in Public Speaking Anxiety and Public Speaking Fear, sponsored by Philipps University Marburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Philipps University Marburg · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This randomized controlled trial examines whether imagery-based extinction memory updating following a standardized virtual reality (VR) exposure session improves the generalization of exposure effects to novel public speaking contexts. Individuals with elevated public speaking anxiety will complete a single-session VR speech exposure. Participants are randomized to (a) standard mental rehearsal of the exposure experience or (b) mental rehearsal plus guided imagery that updates the extinction memory with novel, non-exposed contexts. Generalization is assessed 7-14 days later using a multi-context behavioral approach test (BAT) in vivo and in VR.

Read the detailed description

Exposure-based interventions are highly effective in the treatment of anxiety disorders; however, fear reduction achieved during exposure is often limited to the specific situations and stimuli encountered during treatment. As a result, fear may re-emerge when individuals face novel situations, a phenomenon commonly referred to as return of fear. This limited generalization is assumed to reflect the context- and stimulus-specific nature of extinction learning. While increasing variability across exposure contexts can enhance generalization, this approach typically requires longer treatment duration and increased therapeutic burden. Therefore, strategies that promote extinction generalization without increasing exposure time are of high clinical relevance.

Experimental laboratory research has demonstrated that extinction generalization can be enhanced by updating the extinction memory through mental imagery. Specifically, retrieving a recently acquired extinction memory and integrating novel, non-experienced stimuli or situations through imagination has been shown to reduce fear responses to both imagined and previously unencountered stimuli. This process is thought to increase the accessibility and robustness of inhibitory extinction memories by integrating new information into the existing memory network. The present study aims to translate this experimentally established mechanism into a clinically relevant intervention.

In this randomized controlled trial, individuals with elevated public speaking anxiety complete a standardized, single-session virtual reality (VR) speech exposure consisting of repeated short oral presentations across different VR contexts. Following exposure, participants are randomized to one of two imagery-based post-exposure procedures. In the control condition, participants engage in guided mental rehearsal of the previously experienced VR exposure situations. In the experimental condition, participants additionally update the extinction memory by vividly imagining having the same successful exposure experience in two novel public speaking situations: (1) giving a speech in front of a small real audience and (2) giving a speech in a VR environment with a substantially larger audience than experienced during exposure. These imagined situations are not directly experienced during the intervention but are intended to be integrated into the existing extinction memory through guided imagery.

Generalization of exposure effects is assessed 7-14 days after the intervention using a multi-context behavioral approach test (BAT). The BAT includes oral presentations in (a) situations that were directly experienced during VR exposure, (b) situations that were previously imagined during the extinction memory updating procedure, and (c) novel situations that were neither experienced nor imagined before. This design allows for the differentiation between responses to previously experienced, imagined, and entirely new public speaking contexts, thereby providing a stringent test of extinction generalization.

Primary outcomes include public speaking anxiety at follow-up as well as subjective fear ratings during each behavioral approach test, with a focus on differences between study groups across the different BAT contexts. Secondary outcomes include anticipatory anxiety prior to each BAT and behavioral performance indexed by speech duration. Baseline measures of anhedonia and positive emotionality are assessed to examine individual differences in treatment response.

02

Conditions studied

  • Public Speaking Anxiety
  • Public Speaking Fear

Keywords

  • virtual reality exposure
  • extinction generalization
  • fear extinction
  • exposure therapy
03

In context

Lead sponsor

Philipps University Marburg is the lead sponsor of 116 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • speech anxiety scale score of ≥ 18 on the Personal Report of Communication Apprehension, Public Speaking Subscale (PRCA-PS)
  • Self-report of 18 - 70 years of age

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    VR Exposure + Standard Mental Rehearsal

    Single-session VR exposure intervention: 6 VR speech exposure trials \& Post-exposure standard mental rehearsal

    Behavioral: VR Exposure · Behavioral: Standard Mental Rehearsal

  • Experimental
    VR Exposure + Mental Rehearsal With Extinction Memory Updating

    Single-session VR exposure intervention: 6 VR speech exposure trials \& Post-exposure mental rehearsal with updating the extinction memory with novel, non-exposed contexts

    Behavioral: VR Exposure · Behavioral: Mental Rehearsal With Extinction Memory Updating

Interventions

  • BehavioralVR Exposure

    6 VR speech exposure trials (3 min each; topic: "something you are proud of")

  • BehavioralStandard Mental Rehearsal

    Post-exposure guided imagery: vivid mental rehearsal of the same exposure experience in the same VR contexts (brief, ≤30s each)

  • BehavioralMental Rehearsal With Extinction Memory Updating

    Post-exposure guided imagery: vivid rehearsal of the exposure experience while updating the extinction memory with novel, non-exposed contexts (e.g., speaking to three real listeners; speaking in a new VR context with a larger audience). Brief, ≤30s each

06

What researchers measure

Primary outcomes

  1. Public Speaking Anxiety

    Assessed using the Personal Report of Communication Apprehension, Public Speaking Subscale (PRCA-PS). Scores range from 6 to 30, with higher scores associated with higher public speaking anxiety.

    Time frame: From enrollment to one-week follow-up assessment

  2. Subjective Fear During Behavioral Approach Tests

    Self-reported fear during oral presentations, rated on a scale from 0 (no fear) to 100 (severe fear) during each behavioral approach test. Participants were instructed to speak for up to three minutes and could terminate the task at any time. BAT 1: Oral presentation in vivo in front of 3 real listeners BAT 2: Oral presentation in a simulated videoconference with a large audience (30 listeners) BAT 3: Oral presentation in virtual reality (exposure context 1; familiar) BAT 4: Oral presentation in virtual reality (exposure context 2; familiar) BAT 5: Oral presentation in virtual reality (novel context with \~50 virtual listeners) BAT 6: Oral presentation in virtual reality (novel context with \~100 virtual listeners)

    Time frame: one-week follow-up assessment

Secondary outcomes

  1. Social Anxiety Severity

    Severity of social anxiety symptoms assessed using the Social Phobia Inventory (SPIN). Scores range from 0-68, with higher scores indicating greater social phobia.

    Time frame: From enrollment to one-week follow-up assessment

  2. Anticipatory Anxiety Before BATs

    Self-reported anticipatory anxiety assessed immediately before each behavioral approach test on a scale from 0 (no fear) to 100 (severe fear).

    Time frame: One-week follow-up assessment

  3. Behavioral Performance During BATs (Duration of oral presentation during BATs)

    Duration of oral presentation during each behavioral approach test, measured in seconds. Participants were instructed to speak for up to three minutes and could terminate the task at any time.

    Time frame: One-week follow-up assessment

  4. Valence of Public Speaking

    Self-report measure assessing how participants feel about having to give a speech. Valence is rated on a 7-point Likert scale ranging from extremely unpleasant to extremely pleasant (-3 = extremely unpleasant, -2 = moderately unpleasant, -1= slightly unpleasant, 0 = neutral, 1= slightly pleasant, 2= moderately pleasant, 3=extremely pleasant). Higher scores indicate more pronounced pleasantness.

    Time frame: From enrollment to immediately post-treatment assessment and one-week follow-up assessment

  5. Anticipated Fear of Public Speaking

    Participants rate their anticipated fear of giving a speech using a visual analog scale ranging from 0 (no fear) to 100 (extreme fear).

    Time frame: From enrollment to immediately post-intervention and 1-week follow-up

07

Study locations

1 of 1 sites recruiting
  • Department of Psychology, Philipps-University of Marburg
    Marburg, Hesse 35037, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 7, 2026
StartActual
Nov 26, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07323498
Responsible party
Christoph Benke (Principal Investigator, Philipps University Marburg) — Principal investigator
First posted
Jan 7, 2026
Start date
Nov 26, 2025
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 9, 2026

Study contacts

Christoph Benke, Ph.D.
Contact
christoph.benke@uni-marburg.de
+49 6421 28-24091
Christoph Benke, Ph.D.
principal investigator · Philiips-University of Marburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion